Anti-HCV DAA are needed whatever liver fibrosis is. The cons

Anti-HCV DAA are needed whatever liver fibrosis is. The cons

Bibliographic Details
Main Author:	Pablo Barreiro
Format:	Article
Language:	English
Published:	Elsevier 2016-05-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020312371

Similar Items

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016-05-01)

Evaluation of HCV-related liver fibrosis post-successful DAA therapy
by: Nermine Ehsan, et al.
Published: (2021-06-01)

THE DAAS TREATMENT OF CHRONIC HCV INFECTION AND THE LIVER FIBROSIS EVOLUTION DURING TREATMENT: OUR EXPERIENCE
by: Andreea Rădășan, et al.
Published: (2016-09-01)

The Management of Anemia in Patients with HCV Treated with DAA
by: Stavar Angelica Nela, et al.
Published: (2017-05-01)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019-12-01)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
by: Nicolò de Gennaro, et al.
Published: (2020-03-01)

Treatment and re-treatment results of HCV patients in the DAA era.
by: Felix Piecha, et al.
Published: (2020-01-01)

WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS
by: Giovanni Faria SILVA, et al.

Treatment of HBV/HCV co-infected patients in DAA era
by: Wang Cheng, et al.
Published: (2017-06-01)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
by: Mercedes Márquez-Coello, et al.
Published: (2021-05-01)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021-04-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)

Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
by: Matthew A Burchill, et al.
Published: (2017-01-01)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
by: Julia M Grottenthaler, et al.
Published: (2018-01-01)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
by: Hrvoje Roguljic, et al.
Published: (2021-05-01)

Biochemical scores comparison with TE (fibroscan) in HCV cirrhotic patients treated with DAA
by: Miguel Lino de Magalhães
Published: (2021)

Need to Face Liver Cirrhosis after HCV Cure with Antivirals
by: Vicente Soriano, et al.
Published: (2017-10-01)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
by: A. Maughan, et al.
Published: (2019-05-01)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
by: Julia L. Casey, et al.
Published: (2019-04-01)

Letter to the editor: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT
by: Yuh-Ching Gau, et al.
Published: (2020-11-01)

Reply to letter to the editor: Successful eradication of HCV by short-course DAAs in HCV positive donor to HCV-Negative recipient during Haplo-HSCT
by: Chung-Feng Huang, et al.
Published: (2020-11-01)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
by: Rujipat Wasitthankasem, et al.
Published: (2017-11-01)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
by: Claudia Minosse, et al.
Published: (2021-06-01)

DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.
by: Rosanna Villani, et al.
Published: (2016-01-01)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
by: Yu Zhang, et al.
Published: (2016-01-01)

Whatever Speculation
by: Henk Slager
Published: (2019-11-01)

By Whatever Name
by: Svenn-Arve Myklebost
Published: (2010-09-01)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
by: Gao X, et al.
Published: (2020-12-01)

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?
by: Maka Gogia, et al.
Published: (2018-05-01)

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY
by: A. Budkowska
Published: (2018-12-01)

Whatever You Love
by: Renaud Beeckmans
Published: (2011-01-01)

Whatever Happened to Vera?
by: Henderson, Jo
Published: (2013-12-01)

Whatever : Critical Fashion
by: Tanuwijaya, Karina
Published: (2015)

Whatever Happened to Skill?
by: Grugulis, C. Irena, et al.
Published: (2008)

Any-object-whatever
by: Ting-JiaZhang, et al.
Published: (2017)

"Whatever it takes" is all you need: Monetary policy and debt fragility
by: Camous, A., et al.
Published: (2019)

Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection
by: Claudio M. Mastroianni, et al.
Published: (2014-05-01)

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients
by: Valentina Li Vecchi, et al.
Published: (2013-09-01)

LITERATURE REVIEW IN THE FIELD OF DAAS : DAAS RELATED SECURITY ISSUES IN CLOUD COMPUTING
by: MOHAN, ANEESHA
Published: (2012)

O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
by: A.J. Kwon, et al.
Published: (2017-08-01)